COO of GYRE Therapeutics (NASDAQ: GYRE) sells shares after option exercises
Rhea-AI Filing Summary
GYRE THERAPEUTICS, INC. Chief Operating Officer Weiguo Ye reported option exercises paired with open-market sales of common stock. On May 22 and May 26, he exercised stock options to acquire a total of 7,500 shares of common stock at an exercise price of $0.75 per share and sold 7,500 shares in open-market transactions.
The reported sale prices include $6.0800 per share for 3,500 shares and a weighted average price of $6.1001 per share for 4,000 shares, with individual trades ranging from $6.04 to $6.1051. Following these transactions, Ye’s directly held common stock position is reported at approximately 700,000 shares, indicating the activity mainly reflects option-related liquidity rather than a large change in overall ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 7,500 shares ($40K approx. pre-tax spread)
Exercise and Sale
6 txns
Insider
Ye Weiguo
Role
Chief Operating Officer
Sold
7,500 shs ($46K)
Approx. gross sale proceeds
$46K
Approx. exercise cost
$6K
Approx. pre-tax spread
$40K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,000 | $0.75 | $3K |
| Sale | Common Stock | 4,000 | $6.1001 | $24K |
| Exercise | Stock Option (Right to Buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $0.75 | $3K |
| Sale | Common Stock | 3,500 | $6.08 | $21K |
Holdings After Transaction:
Stock Option (Right to Buy) — 897,395 shares (Direct);
Common Stock — 700,000 shares (Direct)
Footnotes (2)
- F1. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F2. These options are vested in full.
Key Figures
Shares sold May 26: 4,000 shares at $6.1001
Sale price range May 26: $6.04–$6.1051 per share
Shares sold May 22: 3,500 shares at $6.0800
+4 more
7 metrics
Shares sold May 26
4,000 shares at $6.1001
Open-market sale of GYRE common stock on May 26, 2026
Sale price range May 26
$6.04–$6.1051 per share
Price range across multiple GYRE sale transactions
Shares sold May 22
3,500 shares at $6.0800
Open-market sale of GYRE common stock on May 22, 2026
Options exercised May 22
3,500 shares at $0.75
Stock option exercise into GYRE common stock
Options exercised May 26
4,000 shares at $0.75
Stock option exercise into GYRE common stock
Shares following May 26 sale
700,000 shares
Direct GYRE common stock holdings after transaction
Options remaining after May 26
897,395 options
Stock options (right to buy) following derivative transaction
Key Terms
open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), weighted average sale price per share, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vested in full financial
"These options are vested in full."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did GYRE COO Weiguo Ye report in this Form 4 for GYRE?
He reported exercising stock options for 7,500 GYRE shares at $0.75 each and selling 7,500 common shares in the open market, reflecting routine option exercise-and-sell activity rather than a large change in his overall ownership position.
What options did the GYRE COO exercise in the latest Form 4 filing?
He exercised vested stock options covering 3,500 and 4,000 underlying GYRE common shares, each with a conversion or exercise price of $0.75 per share, converting derivative positions into common stock immediately before selling equivalent share amounts.
What is Weiguo Ye’s GYRE common stock ownership after these transactions?
After the reported exercises and sales, his directly held GYRE common stock position is shown around 700,000 shares, indicating that the 7,500-share sale is small relative to his remaining holdings and represents a modest proportion of his total reported ownership.
Were the GYRE COO’s options fully vested at the time of exercise?
Yes. A footnote states that the reported stock options are vested in full, meaning all 7,500 options exercised by the GYRE Chief Operating Officer were fully exercisable when converted into common shares prior to the corresponding open-market sales.